Medica buying Mayo Clinic’s health benefits division

Minnetonka, Minnesota-based Medica has reached a deal with Mayo Clinic to acquire its Mayo Clinic Health Solutions division, also known as MMSI, for an undisclosed sum.

MMSI acts as a third-party administrator for 28 self-insuring companies, including the Mayo Clinic’s own employee health plan, which cover about 260,000 people. A press release said the move “represents a new business arrangement” with opportunities to improve access for complex patients.

“For many years, Mayo Clinic and Medica have each worked to advance health care, improve the consumer experience and drive innovation in health care delivery, technologies and tools,” Medica President and CEO John Naylor said in a statement. “Today, with Medica’s acquisition of MMSI, we can bring greater capabilities and flexibility through new technologies for customers.”

Medica and Mayo Clinic hope to begin the change by the end of 2017, with MMSI’s services transferring to Medica over a two-year period. Some decisions will have to made about the division’s tax status, as Medica is a nonprofit while MMSI is not.

First established in 1986 as Mayo Management Services, MMSI customers and employees shouldn’t notice any change in the immediate future, Medica said. Mayo’s decision to sell the division was motivated by the increasing prevalence of narrow network insurance plans.

"Mayo Clinic has decided to transition to this new arrangement in response to changing external market forces that make it necessary to ensure patients with serious and complex medical conditions have access to Mayo Clinic. It has nothing to do with the quality of work MMSI staff provide," Mayo Clinic spokesman Karl Oestreich said to the Rochester Post-Bulletin.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.